Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) reached a new 52-week low during trading on Tuesday after Deutsche Bank AG lowered their price target on the stock from $68.00 to $54.00. Deutsche Bank AG currently has a buy rating on the stock. Teva Pharmaceutical Industries traded as low as $37.60 and last traded at $37.60, with a volume of 27,128,695 shares trading hands. The stock had previously closed at $41.03.

Several other brokerages have also commented on TEVA. Mizuho restated a “buy” rating and set a $70.00 target price (down previously from $75.00) on shares of Teva Pharmaceutical Industries in a research report on Friday, August 5th. Leerink Swann restated an “outperform” rating and set a $66.00 target price on shares of Teva Pharmaceutical Industries in a research report on Tuesday, August 16th. Guggenheim restated a “buy” rating and set a $80.00 target price on shares of Teva Pharmaceutical Industries in a research report on Monday, August 15th. JPMorgan Chase & Co. restated an “overweight” rating and set a $75.00 target price on shares of Teva Pharmaceutical Industries in a research report on Tuesday, July 26th. Finally, Piper Jaffray Cos. restated a “neutral” rating and set a $57.00 target price (up previously from $55.00) on shares of Teva Pharmaceutical Industries in a research report on Monday, August 8th. Thirteen equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $60.00.

Several institutional investors have recently bought and sold shares of TEVA. Sharkey Howes & Javer raised its position in Teva Pharmaceutical Industries by 21.7% in the second quarter. Sharkey Howes & Javer now owns 2,008 shares of the company’s stock worth $101,000 after buying an additional 358 shares during the last quarter. Hudock Capital Group LLC raised its stake in Teva Pharmaceutical Industries by 37.6% in the second quarter. Hudock Capital Group LLC now owns 2,064 shares of the company’s stock valued at $103,000 after buying an additional 564 shares in the last quarter. WFG Advisors LP raised its stake in Teva Pharmaceutical Industries by 14.0% in the second quarter. WFG Advisors LP now owns 2,080 shares of the company’s stock valued at $104,000 after buying an additional 256 shares in the last quarter. Kistler Tiffany Companies LLC raised its stake in Teva Pharmaceutical Industries by 3.1% in the second quarter. Kistler Tiffany Companies LLC now owns 2,135 shares of the company’s stock valued at $107,000 after buying an additional 64 shares in the last quarter. Finally, Washington Trust Bank raised its stake in Teva Pharmaceutical Industries by 2.7% in the third quarter. Washington Trust Bank now owns 2,232 shares of the company’s stock valued at $103,000 after buying an additional 58 shares in the last quarter. 63.00% of the stock is owned by hedge funds and other institutional investors.

The stock’s 50 day moving average is $43.29 and its 200-day moving average is $49.96. The firm has a market capitalization of $34.80 billion, a P/E ratio of 25.43 and a beta of 0.73.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings data on Tuesday, November 15th. The company reported $1.31 earnings per share for the quarter, topping analysts’ consensus estimates of $1.29 by $0.02. Teva Pharmaceutical Industries had a net margin of 7.56% and a return on equity of 17.77%. The company earned $5.56 billion during the quarter, compared to analyst estimates of $5.71 billion. During the same period in the previous year, the business earned $1.35 EPS. The firm’s revenue for the quarter was up 15.3% on a year-over-year basis. On average, equities research analysts expect that Teva Pharmaceutical Industries Ltd. will post $5.16 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 20th. Investors of record on Monday, December 5th will be issued a $0.34 dividend. This represents a $1.36 dividend on an annualized basis and a yield of 3.57%. Teva Pharmaceutical Industries’s payout ratio is currently 58.39%.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited is a global pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. It has a global portfolio of approximately 1,000 molecules.

5 Day Chart for NYSE:TEVA

Receive News & Stock Ratings for Teva Pharmaceutical Industries Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Ltd. and related stocks with our FREE daily email newsletter.